Company Description At CERN, the European Organization for Nuclear Research, physicists and engineers are probing the fundamental structure of the universe. Using the worlds largest and most complex scientific instruments, they study the basic constituents of
Salary Range:CHF142,100.00 - CHF263,900.00 Job Description SummaryLI#- Hybrid Location: Basel, Switzerland As a Therapeutic Area Biomarker Lead (TABL) in the Biomarker Development (BMD) group, you are accountable for defining and delivering biomarker strategies for the Immunology
At Johnson & Johnson,we believe health is everything. Our strength in healthcare innovation empowers us to build aworld where complex diseases are prevented, treated, and cured,where treatments are smarter and less invasive, andsolutions are personal.Through our
At Johnson & Johnson,we believe health is everything. Our strength in healthcare innovation empowers us to build aworld where complex diseases are prevented, treated, and cured,where treatments are smarter and less invasive, andsolutions are personal.Through our
At Johnson & Johnson,we believe health is everything. Our strength in healthcare innovation empowers us to build aworld where complex diseases are prevented, treated, and cured,where treatments are smarter and less invasive, andsolutions are personal.Through our
Job Description Accountabilities As part of a project team, the role will be to accelerate the learning of fixed cost estimation for chemical manufacturing routes. This cost analysis will be integrated into the engineering project execution
Salary Range CHF 142,100.00 - CHF 263,900.00 Job Description Summary LI#- Hybrid, Location: Basel, Switzerland As a Therapeutic Area Biomarker Lead (TABL) in the Biomarker Development (BMD) group, you are accountable for defining and delivering biomarker
Summary LI#- Hybrid Location: Basel, Switzerland As a Therapeutic Area Biomarker Lead (TABL) in the Biomarker Development (BMD) group, you are accountable for defining and delivering biomarker strategies for the Immunology portfolio across multiple drug development